- Graduate School - UT Southwestern Medical Center (1999-2006), Chemical Biology
- Medical School - University of Minnesota (2006-2009)
- Residency - University of Michigan Health System (2009-2012), General Surgery
- Research Fellowship - University of Michigan Medical School (2012-2014), Translational Oncology
- Residency - University of Michigan Health System (2014-2017), Radiation Oncology

Prasanna Alluri, M.D., Ph.D.
- Radiation Oncology
- Radiation Therapy for Breast Cancer
- Advanced, Inflammatory, Metastatic or Recurrent Breast Cancers
Biography
Prasanna Alluri, M.D., Ph.D., is an Assistant Professor of Radiation Oncology at UT Southwestern Medical Center. He specializes in the treatment of breast cancer.
He earned his medical degree at the University of Minnesota Medical School, and received a Ph.D. in chemical biology from UT Southwestern Medical Center. He then completed a research fellowship in translational oncology and a residency in radiation oncology at the University of Michigan Medical School, where he was also a chief resident.
Dr. Alluri has received many recognitions for both his research contributions and clinical care, including the American Medical Association Research Award, the American College of Surgeons Resident Research Award, and the Making a Difference Award for Outstanding Clinical Care. Most recently, he was a recipient of the Conquer Cancer Foundation of American Society of Clinical Oncology/Breast Cancer Research Foundation’s Young Investigator Award.
He is a member of several professional organizations, including the American Society for Radiation Oncology, the American Society of Clinical Oncology, and the American Association for Cancer Research.
His work has been published in major journals, including Cell Research, Breast Cancer Research, and Journal of the American Chemical Society.
Meet Dr. Alluri
As a physician and scientist, Prasanna Alluri, M.D., Ph.D., brings a unique combination of skills to his patients and colleagues.
His clinical focus is on breast cancer where he sees the entire spectrum of breast cancer patients – from newly diagnosed early stage breast cancer patients seeking curative treatments to metastatic breast cancer patients looking for innovative clinical trials.
Dr. Alluri also directs a research laboratory that's focused on understanding the molecular mechanisms of
treatment resistance in breast cancer.
“Through my research I focus on patients with the most aggressive forms of breast cancer who have failed several lines of treatments,” Dr. Alluri says. “Our goal is to develop new targeted therapies based on a more intricate understanding on what’s driving these cancers.”
Targeted therapies, unlike chemotherapy, are less toxic and more effective. Dr. Alluri’s team is also studying if combining targeted therapies with radiation improves the efficacy of the treatment.
While traditional radiation treatments for breast cancer last six to seven weeks, there are ongoing efforts to shorten the length of treatment.
“With the newer technologies we have, we're investigating how we can significantly shorten treatment duration, while not causing any extra side effects or reducing the treatment’s efficacy,” Dr. Alluri says. “We have many ongoing trials to address this question, and we're one of the leaders in defining new treatment paradigms for breast cancer.”
UT Southwestern's multidisciplinary efforts to treat breast cancer and the breadth of its research expertise are just a few of the reasons why UT Southwestern is an exceptional and unique place to work, according to Dr. Alluri.
“We have to keep pushing the boundaries to improve patient care,” Dr. Alluri says. “The opportunities to work with colleagues who are leaders in clinical care and basic/translational research are truly unmatched. I can’t think of a better place to work.”
Education & Training
Professional Associations & Affiliations
- American Association for Cancer Research (AACR)
- American Society for Radiation Oncology (ASTRO)
- American Society of Clinical Oncology (ASCO)
Honors & Awards
- DocStar Award from The Cary Council of Southwestern Medical Foundation for innovative research in breast cancer 2018
- Young Investigator Award from Conquer Cancer Foundation of ASCO/Breast Cancer Research Foundation 2017
- American College of Surgeon Resident Research Scholar 2012
- Making a Difference Award from the University of Michigan Health System for outstanding patient care 2012
- Making a Difference Award from the University of Michigan Health System for outstanding clinical care 2011
- Elected to University of Minnesota Medical School Chapter Gold Humanism Honor Society 2008
- American Medical Association Foundation Research Award 2006
- Meritorious Research in Biomedical Sciences Award from UT Southwestern Graduate School 2004
- Sigma Xi, The Scientific Research Society 2004
Books & Publications
-
Publications
-
Androgen Receptor (AR) As a Mediator and Biomarker of Radioresistance in Triple-Negative Breast Cancer
C Speers, SG Zhao, A Santola, M Liu, K. Wilder-Romans, PG Alluri, TS Lawrence, F Feng, LJ Pierce npj Breast Cancer 2017 3 29-38 -
Basal-like and triple-negative breast cancers: searching for positives among many negatives.
Alluri P, Newman LA Surgical oncology clinics of North America 2014 Jul 23 3 567-77 -
Estrogen receptor mutations and their role in breast cancer progression.
Alluri PG, Speers C, Chinnaiyan AM Breast cancer research : BCR 2014 Dec 16 6 494 -
BETs abet Tam-R in ER-positive breast cancer.
Alluri PG, Asangani IA, Chinnaiyan AM Cell research 2014 Aug 24 8 899-900 -
Isolation and characterization of coactivator-binding peptoids from a combinatorial library.
Alluri P, Liu B, Yu P, Xiao X, Kodadek T Molecular bioSystems 2006 Nov 2 11 568-79 -
Simple reporter gene-based assays for hairpin poly(amide) conjugate permeability and DNA-binding activity in living cells.
Liu B, Yu P, Alluri PG, Kodadek T Molecular bioSystems 2005 Oct 1 4 307-17 -
A potent transactivation domain mimic with activity in living cells.
Liu B, Alluri PG, Yu P, Kodadek T Journal of the American Chemical Society 2005 Jun 127 23 8254-5 -
Synthetic molecules as antibody replacements.
Kodadek T, Reddy MM, Olivos HJ, Bachhawat-Sikder K, Alluri PG Accounts of chemical research 2004 Sep 37 9 711-8 -
Isolation of protein ligands from large peptoid libraries.
Alluri PG, Reddy MM, Bachhawat-Sikder K, Olivos HJ, Kodadek T Journal of the American Chemical Society 2003 Nov 125 46 13995-4004 -
Microwave-assisted solid-phase synthesis of peptoids.
Olivos HJ, Alluri PG, Reddy MM, Salony D, Kodadek T Organic letters 2002 Nov 4 23 4057-9
-
Androgen Receptor (AR) As a Mediator and Biomarker of Radioresistance in Triple-Negative Breast Cancer
Research
- Using bedside-to-bench-approaches, including next generation clinical sequencing of patient tumors, to develop clinically relevant models of treatment resistance in breast cancer
- Elucidating mechanisms of treatment resistance in breast cancer
- High throughput screening approaches, including large-scale CRISPR and small molecule screens, to identify synthetic lethal drug targets in treatment-refractory breast cancer
- Metabolic imaging approaches to study radiation-induced cardiotoxicity in breast cancer patients
Clinical Focus
- Radiation Therapy for Breast Cancer
- Advanced, Inflammatory, Metastatic or Recurrent Breast Cancers
- Radiation Therapy for Cancer
- Breast Cancers
Links
Showing 1 locations
University Hospital Radiation Oncology Clinic - Moncrief Building
Moncrief Building5801 Forest Park Road
Dallas, Texas 75390 214-645-8525 Directions Parking Info